Effect of Chinese Herbal Medicine Therapy on Overall and Cancer Related Mortality in Patients With Advanced Nasopharyngeal Carcinoma in Taiwan

Chen-Yu Wang1,2†, Tang-Chuan Wang3,4,5†, Wen-Min Liang6, Chien-Hui Hung7,8, Jian-Shiu Chioù6, Chao-Jung Chen9,10, Fuu-Jen Tsai1,2,11, Sheng-Teng Huang1,2, Ta-Yuan Chang6, Ting-Hsu Lin6, Chiu-Chu Liao6, Shao-Mei Huang6, Te-Mao Li2* and Ying-Ju Lin2,9*

1Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan, 2School of Chinese Medicine, China Medical University, Taichung, Taiwan, 3Department of Public Health, China Medical University, Taichung, Taiwan, 4School of Medicine, China Medical University, Taichung, Taiwan, 5Department of Otolaryngology-Head and Neck Surgery, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, 6Department of Health Services Administration, China Medical University, Taichung, Taiwan, 7Graduate Institute of Clinical Medical Sciences, Chang-Gung University, Taoyuan, Taiwan, 8Division of Infectious Diseases, Chang Gung Memorial Hospital Chiayi Branch, Chiayi, Taiwan, 9Genetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, 10Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan, 11Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan

Nasopharyngeal carcinoma (NPC) is a head and neck cancer involving epithelial squamous-cell carcinoma of the nasopharynx that mainly occurs in individuals from East and Southeast Asia. We investigated whether Chinese herbal medicine (CHM) as a complementary therapy offers benefits to these patients. We retrospectively evaluated the Taiwan Cancer Registry (Long Form) database for patients with advanced NPC, using or not using CHM, between 2007–2013. Cox proportional-hazard model and Kaplan–Meier survival analyses were applied for patient survival. CHM-users showed a lower overall and cancer-related mortality risk than non-users. For advanced NPC patients, the overall mortality risk was 0.799-fold for CHM-users, after controlling for age, gender, and Charlson comorbidity index (CCI) score (Cancer stages 3 + 4: adjusted hazard ratio [aHR]: 0.799, 95% confidence interval [CI]: 0.676–0.943, p = 0.008). CHM-users also showed a lower cancer-related mortality risk than non-users (aHR: 0.71, 95% CI: 0.53–0.96, p = 0.0273). Association rule analysis showed that CHM pairs were Ban-Zhi-Lian (BZL; Scutellaria barbata D.Don) and For single herbs, Bai-Hua-She-She-Cao (Herba Hedyotis Diffusae; Scleromitrion diffusum (Willd.)R.J.Wang (syn. Hedyotis diffusa Willd.) and Mai-Men-Dong (MMD; Ophiopogon japonicus (Thunb.) Ker Gawl.), and Gan-Lu-Yin (GLY) and BHSSC. Network analysis revealed that BHSSC was the core CHM, and BZL, GLY, and Xiu-Ying-Fei-Tang (XYQFT) were important CHMs in cluster 1. In cluster 2, ShengDH, MMD, Xuan-Shen (XS; Scrophularia ningpoensis Hensl.), and Gua-Lou-Gen (GLG; Trichosanthes kirilowii Maxim.) were important CHMs. Thus, as a complementary therapy, CHM, and particularly the 8 CHMs identified, are important for the treatment of advanced NPC patients.

Keywords: advanced nasopharyngeal carcinoma, overall mortality, chinese herbal medicine, association rule, network analysis
INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a head and neck cancer involving epithelial squamous-cell carcinoma of the nasopharynx (Ferlay et al., 2019), which mainly occurs in individuals from East and Southeast Asia (Cao et al., 2011; Ferlay et al., 2019). The global incidence of NPC is less than 1 per 100,000 person-years; however, in Taiwan, its incidence is 2.8–6.6 per 100,000 person-years (Hsu et al., 2011; Fan et al., 2018). Furthermore, in Taiwan, NPC is the most second most common head and neck cancer in males and females, respectively (Huang et al., 2015). NPC treatment involves integration of radiotherapy, chemotherapy, and surgery (Perri et al., 2019). The main therapies for NPC are radiotherapy alone for early stage (T1–N0M0 stage) or combined with both chemotherapy and radiotherapy for advanced stages (T2N0–T4N3M0) (Perri et al., 2019). With radiotherapy alone or chemotherapy in patients with early or advanced NPC, the 5-years survival rate approaches 90% (Blanchard et al., 2015). However, it may cause complications (Langendijk et al., 2008; Jensen et al., 2010), such as mucositis, dermatitis, xerostomia, dysphagia, hyposalivation, xerostomia, radiation caries, sensorineural hearing loss, radioactive osteonecrosis, triceps, temporal lobe injury, and hypothyroidism. Additionally, 8–10% of these patients develop therapeutic resistance and have recurrent disease and distant metastasis (Perri et al., 2011).

There is a need for alternative therapies that can be used in combination with conventional therapies (Salehi et al., 2019a; Salehi et al., 2019b). Chinese herbal medicine (CHM) is cost-effective and has relatively few side effects over long-term usage, and patients with cancer may choose CHM as their integrative, alternative, and complementary therapy to reduce complications from conventional therapies and to improve the overall survival rate in Taiwan (Ye et al., 2015; Hung et al., 2017; Kuo et al., 2018; Li et al., 2018). CHM shows anti-cancer activity via multiple specific targets, synergistic interactions with chemotherapy drugs, and minimal, acceptable side-effects (Aung et al., 2017). Furthermore, CHM and the related natural compounds exhibit protective effects against NPC (Kong et al., 2018; Song et al., 2019; Zhao et al., 2019; Guo et al., 2020). Consequently, these are investigated as alternative therapies for use, combined with conventional therapies, to improve the treatment of patients with NPC, particularly advance-stage NPC (Chen et al., 2019).

To evaluate the effect of CHM as a complementary therapy in patients with NPC, particularly advanced-stage NPC, we used a database in Taiwan to explore the effect of CHM on overall mortality. The CHM prescription pattern in NPC with lower overall mortality was also investigated.

MATERIALS AND METHODS

Database Source
This study was performed using the Taiwan Cancer Registry (Long Form) database of the National Health Insurance Research Database (NHIRD) (http://tcr.cph.ntu.edu.tw/main.php?Page=N1) (Chiang et al., 2019). There were detailed TNM stage (TNM (tumor, lymph node, and metastasis), cancer stages and cause of death in this database. This database offered longitudinally linked data for each individual during the period between 2003 and 2016. All personal data were decoded. Informed consent was not required. This study was approved by the Institutional Review Board of the China Medical University Hospital (ethics approval number: CMUH107-REC3-074(CR1)).

Study Subjects
The International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) system was used to identify patients with nasopharyngeal carcinoma (NPC) (ICD-9-CM-code: 147). Overall, 7,150 patients with NPC were identified between 2007–2013 (Figure 1). After excluding patients with incorrect data, missing data, malignancy (ICD9-CM-code: 140–208), no radiotherapy or chemotherapy, and cumulative CHM use of <14 days, 1,454 patients were designated as CHM-users and 1,128 patients as non-users, who did not use CHMs during the follow-up period. To diminish potential bias due to confounders, age, gender, Charlson comorbidity index (CCI) score, and cancer stage CHM-users and non-users were applied to match the two groups for a 1:1 ratio using propensity score matching. After matching, there were 992 matched CHM/non-CHM-user pairs (Figure 1 and Table 1). The date was defined as the index date when 14 cumulative CHM days were completed. The CHM-users continued to use CHMs during the follow-up period. The date of death, the date of withdrawal from the NHIRD database, or the date of the end of follow-up (December 31, 2016) was defined as the study endpoint.

Chinese Herbal Medicine
CHM products used in NPC patients contain two types: single herb and herbal formula (Supplementary Table S1). The herbal formula combines at least two single herbs. A single herb is a part of a plant, such as seeds, fruits, flowers, roots, stems, or leaves. Single herb CHM may also be organs of animals, insects, or minerals. In this study, NPC patients received CHM prescriptions from licensed Chinese medicine doctors, and these CHM prescriptions were produced by pharmaceutical manufacturers following Good Manufacturing Practice in Taiwan (Li et al., 2018; Tsai et al., 2019a; Cheng et al., 2019).

Association Rule
The CHM prescription profile was investigated using association rule mining (Yang et al., 2013). The association rule was also implemented as previously described for paired CHM combinations (Tsai et al., 2019b; Cheng et al., 2019; Tsai et al., 2019c; Chen et al., 2021; Tsai et al., 2020) using SAS software (version 9.4; SAS Institute, Cary, NC, USA). The strength of association between paired CHM combinations (CHM products X and Y) was shown using the support value (X) (%), confidence value (CHM_X→CHM_Y; %), and lift value as previously described (Tsai et al., 2019c; Chen et al., 2021; Tsai et al., 2020) (Table 4).
Network Analysis

Network analysis for CHM clusters was accomplished as previously described (Tsai et al., 2019b; Cheng et al., 2019; Tsai et al., 2019c; Chen et al., 2021; Tsai et al., 2020) using Cytoscape (https://cytoscape.org/, version 3.7.0). The herbal formula is shown as a red circle, and a single herb is expressed as a green circle. The circle size indicates the prescription frequency of the CHM. The line size signifies the support value between paired CHM products. Line color displays the lift value between paired CHM products. The thicker and darker connection line shows a stronger connection strength between the paired CHM products.

Statistical Analysis

Categorical data (age, gender, TNM [tumor, lymph node, and metastasis] stage, cancer stage, and surgery) are shown as numbers (percentages), and the Chi-squared test was applied to evaluate the differences between CHM-users and non-users (Table 1). Crude and adjusted Cox proportional hazard models were used to estimate the risk of overall mortality (Table 2). The adjustment factors included age, gender, CHM use, CCI score, cancer stage, and surgery (Table 2). NPC patients were stratified according to cancer stage (Table 3 and Figure 4). For NPC patients in cancer stages 1 + 2, patients were stratified by age, gender, and CCI (Table 3 and Figure 4). For NPC patients in cancer stages 3 + 4, patients were also stratified by age, gender, and CCI (Table 3 and Figure 4). The adjustment factors included age, gender, CHM use, and CCI score (Table 3). Kaplan–Meier curves and log-rank tests were performed to assess the cumulative incidence of overall mortality between the two groups (Figure 3). p-values of less than 0.05 were considered statistically significant. All analyses were completed using SAS software (version 9.4; SAS Institute).
TABLE 1 | Demographic characteristics of patients with nasopharyngeal carcinoma.

| Characteristics | CHM users | | Non-users | | Total subjects | | Matched subjects | | P-value |
|-----------------|-----------|-----------------|-----------|-----------------|-----------|-----------------|-----------|-----------------|-----------|
|                 | CHM users | Non-users | P-value  | CHM users | Non-users | P-value  | CHM users | Non-users | P-value  |
| Age (years old) |           |           | 0.015    |           |           | 0.945    |           |           | 0.001    |
| Age<50          |           |           |          |           |           |          |           |           |          |
| Age50<60        | 774 (53.23%) | 538 (47.52%) |          | 494 (49.80%) | 489 (49.29%) |          | 494 (49.80%) | 489 (49.29%) |          |
| Age60           | 443 (30.47%) | 380 (33.69%) |          | 320 (32.26%) | 327 (32.96%) |          | 320 (32.26%) | 327 (32.96%) |          |
| Gender          |           |           | 0.001    |           |           | 0.901    |           |           | 0.918    |
| Male            | 1054 (72.49%) | 971 (86.08%) |          | 842 (84.88%) | 840 (84.68%) |          | 842 (84.88%) | 840 (84.68%) |          |
| Female          | 400 (27.51%) | 157 (13.92%) |          | 150 (15.12%) | 152 (15.32%) |          | 150 (15.12%) | 152 (15.32%) |          |
| CCI score (Mean±SD) | 0.87±1.22 | 0.67±1.11 | 0.001    | 0.72±1.06  | 0.71±1.13  | 0.001    | 0.72±1.06  | 0.71±1.13  | 0.001    |
| T-stage         |           |           | 0.001    |           |           | 1.000    |           |           |          |
| T1-T2           | 845 (58.12%) | 576 (51.06%) |          | 539 (54.33%) | 539 (54.33%) |          | 539 (54.33%) | 539 (54.33%) |          |
| T3-T4           | 609 (41.88%) | 552 (48.94%) |          | 453 (45.67%) | 453 (45.67%) |          | 453 (45.67%) | 453 (45.67%) |          |
| N-stage         |           |           | 0.001    |           |           | 0.529    |           |           |          |
| N0              | 179 (12.31%) | 123 (10.90%) |          | 120 (12.10%) | 115 (11.59%) |          | 120 (12.10%) | 115 (11.59%) |          |
| N1-N2           | 1072 (73.73%) | 766 (67.91%) |          | 706 (71.17%) | 692 (69.76%) |          | 706 (71.17%) | 692 (69.76%) |          |
| N3-N4           | 203 (13.96%) | 239 (21.99%) |          | 166 (16.73%) | 185 (18.65%) |          | 166 (16.73%) | 185 (18.65%) |          |
| M-stage         |           |           | 0.001    |           |           | 0.196    |           |           |          |
| M0              | 1398 (96.15%) | 1048 (92.91%) |          | 945 (95.26%) | 932 (93.95%) |          | 945 (95.26%) | 932 (93.95%) |          |
| M1              | 56 (3.85%) | 80 (7.09%) |          | 47 (4.74%)  | 60 (6.05%)  |          | 47 (4.74%)  | 60 (6.05%)  |          |
| Cancer stage    |           |           | 0.001    |           |           | 0.983    |           |           |          |
| No              | 47 (3.23%) | 31 (2.75%) |          | 32 (3.23%)  | 31 (3.13%)  |          | 32 (3.23%)  | 31 (3.13%)  |          |
| 2               | 392 (26.96%) | 231 (20.48%) |          | 223 (22.08%) | 223 (22.48%) |          | 223 (22.08%) | 223 (22.48%) |          |
| 3               | 566 (39.06%) | 381 (33.78%) |          | 359 (36.19%) | 366 (36.90%) |          | 359 (36.19%) | 366 (36.90%) |          |
| 4               | 447 (30.74%) | 485 (43.00%) |          | 372 (37.50%) | 372 (37.50%) |          | 372 (37.50%) | 372 (37.50%) |          |
| Surgery         |           |           |          |           |           |          |           |           |          |
| No              | 1401 (96.35%) | 1066 (94.50%) | 0.024    | 948 (95.56%) | 942 (94.96%) |          | 948 (95.56%) | 942 (94.96%) |          |
| Yes             | 53 (3.65%) | 62 (5.50%) |          | 44 (4.44%)  | 50 (5.04%)  |          | 44 (4.44%)  | 50 (5.04%)  |          |

N, number; CHM, Chinese herbal medicine; CCI, Charlson comorbidity index; T-stage, tumor stage; N-stage, lymph nodes stage; M-stage, metastasis stage.

Demographic Characteristics
For CHM-users and non-users, age, gender, CCI score, TNM stage, cancer stage, and surgery differed significantly (total subjects; p-value < 0.05; Table 1). To decrease confounding effects, propensity score matching was performed, after which there were no significant differences in demographic characteristics between the two matched users (p-value > 0.05).

Overall Mortality
In the investigation of overall mortality in patients with NPC (Table 2), the crude Cox proportional hazard model revealed significant differences in age, gender, CHM use, CCI score, and cancer stage. After adjusting for these variances, the adjusted Cox proportional hazard model showed that patients aged over 60 years had a higher overall mortality risk than those aged below 50 years (Table 2; adjusted hazard ratio [aHR]: 2.36, 95% CI: 1.90–2.93, p < 0.0001). Females showed a lower risk of overall mortality than males (Table 2; aHR: 0.73, 95% CI: 0.57–0.95, p = 0.0173). Patients with cancer stage 3 had a higher risk of overall mortality than those with cancer stage 1 (Table 2; aHR: 2.82, 95% CI: 1.30–5.85, p = 0.0088). Patients with cancer stage 4 had a higher risk of overall mortality than those with cancer stage 1 (Table 2; aHR: 6.86, 95% CI: 3.19–14.73, p < 0.0001).

CHM-users showed a lower overall mortality risk than non-users (aHR: 0.78, 95% CI: 0.67–0.92, p = 0.0024; Table 2). Kaplan–Meier survival plots revealed the difference in the cumulative incidence of overall mortality between the two
groups of users (Figure 2; \( p < 0.0001 \), log-rank test). The cumulative incidence of overall mortality was significantly higher in non-users.

The hazard ratios for overall mortality in these NPC patients were separated into subgroups according to cancer stage. Among these subgroups, a lower overall mortality risk was observed in
CHM-users in patients with cancer stages 3 + 4 (advanced stages; aHR: 0.799, 95% CI: 0.676–0.943, p = 0.008) (Table 3 and Figure 4).

**Chinese Herbal Medicine Prescription Pattern**

The herbal composition and related prescription frequency information for patients with NPC are listed in Table S1. Based on prescription frequency, Ban-Zhi-Lian (BZL) was the most commonly prescribed herbal formula. Xin-Yi-Qing-Fei-Tang (XYQFT) was the second herbal formula. For single CHM, Chinese herbal medicine; LHS, left-hand-side; RHS, right-hand-side.

TABLE 4 | Ten most commonly used pairs of CHM products for patients with nasopharyngeal carcinoma in Taiwan.

| CHM products (LHS, X) | Chinese name | Frequency of prescriptions of X product | CHM products (RHS, Y) | Chinese name | Frequency of prescriptions of Y product | Frequency of prescriptions of X and Y products | Support (X) (%) | Confidence (X→Y) (%) | Lift |
|-----------------------|--------------|----------------------------------------|-----------------------|--------------|---------------------------------------|-----------------------------------------------|--------------|----------------------|------|
| Ban-Zhi-Lian (BZL)    | 半枝蓮       | 2040                                   | Bai-Hua-She-She-Cao (BHSSC) | 舌草         | 5719                                  | 1596                                          | 4.9          | 78.2                 | 4.5  |
| Sheng-Di-Huang (ShengDH) | 生地黃     | 2232                                   | Mai-Men-Dong (MMD)       | 咽門冬       | 3140                                  | 1041                                          | 3.2          | 46.6                 | 4.9  |
| Gan-Lu-Yin (GLY)      | 麥門冬       | 5185                                   | Bai-Hua-She-She-Cao (BHSSC) | 舌草         | 5719                                  | 908                                           | 3.0          | 19.2                 | 1.1  |
| Mai-Men-Dong (MMD)    | 麥門冬       | 3140                                   | Xuan-Shen (XS)           | 玄參         | 3323                                  | 930                                           | 2.8          | 29.6                 | 2.9  |
| Sheng-Di-Huang (ShengDH) | 生地黃     | 2232                                   | Xuan-Shen (XS)           | 玄參         | 3323                                  | 876                                           | 2.7          | 39.2                 | 3.9  |
| Xin-Yi-Qing-Fei-Tang (XYQFT) | 辛夷清     | 3812                                   | Bai-Hua-She-She-Cao (BHSSC) | 舌草         | 5719                                  | 823                                           | 2.5          | 21.6                 | 1.2  |
| Gua-Lou-Gen (GLG)     | 桔梗根       | 3156                                   | Bai-Hua-She-She-Cao (BHSSC) | 舌草         | 5719                                  | 781                                           | 2.4          | 24.7                 | 1.4  |
| Gua-Lou-Gen (GLG)     | 桔梗根       | 3156                                   | Gan-Lu-Yin (GLY)         | 舌草         | 5185                                  | 747                                           | 2.3          | 23.7                 | 1.5  |
| Mai-Men-Dong (MMD)    | 麥門冬       | 3140                                   | Bai-Hua-She-She-Cao (BHSSC) | 舌草         | 5719                                  | 735                                           | 2.2          | 23.4                 | 1.3  |
| Mai-Men-Dong (MMD)    | 麥門冬       | 3140                                   | Gua-Lou-Gen (GLG)        | 桔梗根       | 3156                                  | 729                                           | 2.2          | 23.2                 | 2.4  |

CHM-users in patients with cancer stages 3 + 4 (advanced stages; aHR: 0.799, 95% CI: 0.676–0.943, p = 0.008) (Table 3 and Figure 4).

**DISCUSSION**

The long-term therapeutic effects of CHM in patients with NPC, particularly advanced-stage NPC, remain to be elucidated (Kim et al., 2015; Song et al., 2019). In our study, with the TNM and cancer stage information and NPC patients identified from the database of the Taiwan Cancer Registry (Long Form) of the NHIRD, we were able to assess the CHM effects for long-term use in NPC patients with advanced-stage disease (cancer stages 3 + 4). NPC patients who used CHM had lower overall and cancer-related mortality than those who did not use CHM after a 7-years follow-up. There was 88.2% of NPC patients who had died from the various forms of cancer...
There were 81.3% of NPC patients who had died from NPC cancer (ICD9-CM-code: 147; Supplementary Figure S2). Only 6.9% of NPC patients who had died from other than NPC cancer (malignancies; ICD9-CM-code: 140–208, except for 147; Supplementary Figure S2). There was only 1.5% of NPC patients who had died from cardiocerebrovascular diseases (ICD9-CM-code: 390–459; Supplementary Figure S2). For NPC patients, CHM-users showed a lower cancer-related mortality risk than non-users (Supplementary Table S9; Figure S6). Also, the NPC-related mortality risk was lower for CHM users after controlling for age, gender, and CCI score for these NPC patients (Supplementary Table S10; Figure S7).

For advanced NPC patients, the overall mortality risk was 0.799-fold (95%CI: 0.676–0.943) for CHM-users after controlling for age, gender, and CCI score. The dose and duration of using CHM was associated with a reduced risk of overall mortality among patients with NPC (Supplementary Tables S3–S8; Figures S1–S3). There was 88.6% of advanced NPC patients who had died from the various forms of cancer (malignancies; ICD9-CM-code: 140–208; Supplementary Figure S5). There were 82.9% of advanced NPC patients who had died from...
NPC cancer (ICD9-CM-code: 147; Supplementary Figure S5). Only 5.7% of advanced NPC patients who had died from other than NPC cancer (malignancies; ICD9-CM-code: 140–208, except for 147; Supplementary Figure S5). There was only 1.7% of advanced NPC patients who had died from cardiocerebrovascular diseases (ICD9-CM-code: 390–459; Supplementary Figure S5). For advanced NPC patients, CHM-users showed a lower cancer-related mortality risk than non-users (Supplementary Table S11; Figure S8). Similar result was also observed in the NPC-related mortality. The NPC-related mortality risk was lower for CHM users after controlling for age, gender, and CCI score for these advanced NPC patients (Supplementary Table S13; Figure S9). Furthermore, we found that eight CHMs were important for these advanced NPC patients by association rules and network analyses. These results provide the utility of clinical CHM as a complementary therapy for patients with advanced NPC.

We enrolled primary NPC patients who received both radiotherapy and chemotherapy. Approximately 80% of these patients were <60 years old and about 80% were male. Our results are similar to those of previous studies (Song et al., 2019). NPC patients in Taiwan were characterized by more males, and 80% of them were under 60 years old in another study (Song et al., 2019). The 5-years overall mortality for NPC patients was approximately 30% in our study, which is in agreement with previous studies (Ji et al., 2019; Zhu et al., 2019). We found that the 5-years overall mortality for patients with NPC was about 25% when patients used CHM. Several Chinese herbs and compounds exhibit protective effects against NPC (Kong et al., 2018; Song et al., 2019; Zhao et al., 2019; Guo et al., 2020). Our results showed the protective effects of the clinical use of CHMs against overall mortality in NPC patients, particularly those with advanced stages.

Our association rule analysis showed that the most commonly used CHM pairs were BZL $\rightarrow$ BHSSC, followed by ShengDH $\rightarrow$ MMD, and GLY $\rightarrow$ BHSSC. Our network analysis showed that, in cluster 1, BHSSC showed the core CHM, and BZL, GLY, and XYQFT were nearby CHMs. In cluster 2, ShengDH, MMD, XS, and GLG were important CHMs.

We identified single herbs, including BZL, BHSSC, ShengDH, MMD, XS, and GLG. Among these single herbs, BZL and BHSSC show anti-cancer and anti-inflammatory activities (Perez et al.,...
activities (Ong et al., 2004; Han et al., 2010; Daker et al., 2012; Peng et al., 2018). Notably, apigenin also inhibits Epstein–Barr virus (EBV) reactivation (Wu et al., 2017). Scleromitrion diffusum (Willd.) R.J.Wang (syn. Hedyotis diffusa Willd. (Rubiaceae family)). Natural compounds of BHSSC, including shecaocerenoside A, shecaoiridoidisde C, coumarin, and quercetin, exhibit anti-tumor activity, including human NPC cells (Wang et al., 2017; Peng et al., 2018).

GLY contains ten single herbs. GLY has shown anti-NPC activity in NPC patients (Song et al., 2019). The GLY extract also shows anti-angiogenic effects (Pan et al., 2010). Our advanced NPC patients also used GLY, with a better survival rate. The natural compound epigallocatechin-3-gallate (EGCG) is from GLY and inhibits human NPC cell migration by suppressing MMP-2 expression (Ho et al., 2019). EGCG also suppresses NPC cell growth by attenuating STAT3 activation (Lin et al., 2014). 5,7-dihydroxyflavone promotes human NPC cell apoptosis via tumor necrosis factor-related apoptosis-inducing ligands (Li et al., 2011). Genistein induces NPC cell growth inhibition and G2/M arrest (Han et al., 2010). Genistein also suppresses NPC stem cell growth via sonic hedgehog signaling (Zhang et al., 2019). Other natural compounds of GLY, including apigenin, coumarin, and quercetin show significant cytotoxic activities against NPC cells (Ong et al., 2004; Dai et al., 2018).

XYQFT contains 10 single herbs and is prescribed to treat respiratory-related diseases, including asthma and allergic rhinitis (Yen et al., 2015; Lo et al., 2020). XYQFT also contains natural compounds, including EGCG, apigenin, coumarin, genistein, and quercetin, which exhibit anti-NPC activities (Ong et al., 2004; Han et al., 2010; Daker et al., 2012; Lin et al., 2014; Peng et al., 2018; Ho et al., 2019; Zhang et al., 2019). Furthermore, 1,3,8-trihydroxy-6-methylanthraquinone (emodin) from XYQFT inhibits EBV reactivation and suppresses NPC cell proliferation (Ma et al., 2017; Wu et al., 2019). The 3-phenyl-1-propenal (trans-cinnamaldehyde) inhibits NPC cells (Daker et al., 2013).

This study demonstrated that complementary CHM therapy may reduce overall and cancer related mortality among advanced NPC patients. There are eight clinically used CHM products that are potentially useful for advanced NPC patients. However, the actual dose of specific CHMs in this prescription for patients was unknown, and the metabolism of the co-prescription pattern in humans, as well as potential confounders (i.e., body mass index, fatty tissue, lifestyle, personalized treatments, social-economic status, and cigarette smoking etc.), were not clarified in this study. Therefore, further randomized controlled trials and functional investigations of these potentially useful CHM products are necessary to validate their efficacy and safety in these patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by the Institutional Review Board of the China Medical University Hospital (ethics approval number: CMUH107-REC3-074(CR1)). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

C-YW, T-CW, T-ML, and Y-JL wrote the manuscript and interpreted the data. W-ML, C-HH, J-SC, C-JC, T-HL, C-CL, and S-MH collected, assembled, and analyzed the data. W-ML, F-JT, S-TH, T-YC, T-ML, and Y-JL provided the study materials. T-ML and Y-JL designed, conceived the study, and amended the manuscript.

FUNDING

This study was supported by grants from the China Medical University, Taiwan (CMU108-MF-32, CMU108-S-15, and CMU108-S-17), the China Medical University Hospital, Taiwan (DMR-109-145, DMR-109-188, and DMR-109-192), and the Ministry of Science and Technology, Taiwan (MOST 106-2320-B-039 -017 -MY3, MOST 108-2314-B-039-044-MY3, and MOST 109-2320-B-039-035-MY3). The funding entities for this study had no role in the study design, data collection, data analysis, interpretation, or authorship of this manuscript.

ACKNOWLEDGMENTS

We are grateful to the Health Data Science Center at the China Medical University Hospital for providing administrative, technical, and funding support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.607413/full#supplementary-material.
REFERENCES

Aung, T. N., Qu, Z., Kortschak, R. D., and Adelson, D. L. (2017). Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. *Int. J. Mol. Sci.*, 18, 656. doi:10.3390/ijms18030656

Blanchard, P., Lee, A., Marguet, S., Leclercq, J., Ng, W. T., Ma, J., et al. (2015). Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol.*, 16, 645–655. doi:10.1016/S1470-2045(15)01269-9

Cao, S. M., Simons, M. J., and Qian, C. N. (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. *Chin. J. Cancer*, 30, 114–119. doi:10.5732/cjc.010.10377

Chen, Y. P., Chan, A. T. C., Le, Q. T., Blanchard, P., Sun, Y., and Ma, J. (2019). Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan. *Cin. Otolaryngol.*, 40, 327–334. doi:10.1111/coa.12371

Huang, W. Y., Lin, C. L., Lin, C. Y., Jen, Y. M., Lo, C. H., Sung, F. C., et al. (2015). Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study. *J. Ethnopharmacol.*, 169, 168–174. doi:10.1016/j.jep.2017.02.004

Jensen, S. B., Pedersen, A. M., Vissink, A., Andersen, E., Brown, C. G., Davies, A. N., et al. (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. *Supportive Care Cancer*, 18, 1039–1060. doi:10.1007/s00520-010-0827-8

Ji, M. F., Sheng, W., Cheng, W. M., Ng, M. H., Wu, B. H., Yu, X., et al. (2019). Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. *Ann. Oncol.*, 30, 1630–1637. doi:10.1093/annonc/mdz231

Kim, W., Lee, W. B., Lee, J., Min, B. L., Lee, H., and Cho, S. H. (2015). Traditional herbal medicine as adjunctive therapy for nasopharyngeal cancer: a systematic review and meta-analysis. *Integr. Cancer Ther.*, 14, 212–220. doi:10.1177/1534734615572881

Kong, L., Li, X., Wang, H., He, G., and Tang, A. (2018). Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. *Biomed. Pharmacother.* 106, 342–348. doi:10.1016/j.biopha.2018.06.143

Kuo, Y. T., Liao, H. H., Chang, J. H., Wu, M. Y., Chen, B. C., Chang, M. C., et al. (2016). Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: a nationwide population-based cohort study. *Integr. Cancer Ther.*, 17, 411–422. doi:10.1177/1534735417722224

Langendijk, J. A., Doormaert, P., Verdonck-De Leeuw, I. M., Leemans, C. A., Aaronson, N. K., and Slotman, B. J. (2008). Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. *J. Clin. Oncol.*, 26, 3770–3776. doi:10.1200/JCO.2007.14.6647

Li, R., Zhao, Y., Chen, J., Shao, S., and Zhang, X. (2014). Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells. *Mol. Med. Rep.*, 9, 413–418. doi:10.3892/mmr.2013.1836

Li, T. M., Yu, Y. H., Tsai, F. J., Cheng, C. F., Wu, Y. C., Ho, T. J., et al. (2018). Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. *J. Ethnopharmacol.*, 213, 92–100. doi:10.1016/j.ijep.2017.10.031

Li, X., Wang, J. N., Huang, J. M., Xiong, X. K., Chen, M. F., Ong, C. N., et al. (2011). Chrysyrone promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines. *Toxicol. Vitro*, 25, 630–635. doi:10.1016/j.tiv.2010.12.013

Lin, C. H., Chao, I. K., Hung, P. H., and Chen, Y. J. (2014). EGGC inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation. *Int. J. Clin. Exp. Pathol.*, 7, 2372–2381.

Lo, P. C., Lin, S. K., and Lai, J. N. (2020). Long-term use of Chinese herbal medicine therapy reduced the risk of asthma hospitalization in school-age children: a nationwide population-based cohort study in Taiwan. *J. Tradit. Complement. Med.*, 10, 141–149. doi:10.1016/j.jtcme.2019.04.005

Ma, L., Yang, Y., Yin, Z., Liu, M., Wang, L., Chen, L., et al. (2017). Emodin suppresses the nasopharyngeal carcinoma cells by targeting the chloride channels. *Biomed. Pharmacother.* 90, 615–625. doi:10.1016/j.biopha.2017.03.088

Ong, C. S., Tran, E., Nguyen, T. T., Ong, C. K., Lee, S. K., Lee, J. J., et al. (2004). Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. *Oncol. Rep.*, 11, 727–733. doi:10.3892/or.11.3.727

Pan, C. H., Hsieh, I. C., Liu, F. C., Hsieh, W. T., Sheu, M. J., Koizumi, A., et al. (2010). Effects of a Chinese herbal health formula, “Gan-Lu-Yin”, on angiogenesis. *J. Agric. Food Chem.*, 58, 7685–7692. doi:10.1021/jf1002254

Peng, L., Huang, Y. T., Chen, J., Zhuang, Y. X., Zhang, F., Chen, J. Y., et al. (2018). Osthole sensitizes with radiotherapy to suppress tumorigenesis of human nasopharyngeal carcinoma in vitro and in vivo. *Cancer Manag. Res.*, 10, 5471–5477. doi:10.2147/CMAR.S182798

Perez, A. T., Arun, B., Tripathy, D., Tagliaferri, M. A., Shaw, H. S., Kimmick, G. G., et al. (2010). A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. *Breast Cancer Res. Treat.*, 120, 111–118. doi:10.1007/s10549-009-0678-5
Perri, F., Bosso, D., Buonnerba, C., Lorenzo, G. D., and Scarpati, G. D. (2011). Locally advanced nasopharyngeal carcinoma: current and emerging treatment strategies. World J. Clin. Oncol. 2, 377–383. doi:10.5306/wjco.v2i12.377

Perri, F., Della Vittoria Scarpati, G., Caponigro, F., Jonna, F., Longo, F., Buonopane, S., et al. (2019). Management of recurrent nasopharyngeal carcinoma: current perspectives. Onco Targets Ther. 12, 1583–1591. doi:10.2147/OTT.S188148

Salehi, B., Ata, A., Nanjangud, V. A. K., Sharopov, F., Ramirez-Alarcon, K., Ruiz-Ortega, A., et al. (2019a). Antidiabetic potential of medicinal plants and their active components. Biomolecules 9, 351. doi:10.3390/biom9100351

Salehi, B., Upadhyay, S., Erdogan Orhan, I., Kumar Jugran, A., S, L. D. J., D, A. D., Perri, F., Della Vittoria Scarpati, G., Caponigro, F., Ionna, F., Longo, F., et al. (2019b). Therapeutic potential of alpha- and beta-pinene: a miracle gift of nature. Biomolecules 9, 738. doi:10.3390/biom910738

Song, Y. C., Hung, K. F., Liang, K. L., Chiang, J. H., Huang, H. C., Lee, H. J., et al. (2019). Adjunctive Chinese herbal medicine therapy for nasopharyngeal carcinoma: clinical evidence and experimental validation. Head Neck 41, 2860–2872. doi:10.1002/hed.25766

Tsai, F. J., Cheng, C. F., Chen, C. J., Lin, C. Y., Wu, Y. F., Li, T. M., et al. (2019a). Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 57, 30–38. doi:10.1016/j.phymed.2018.09.237

Tsai, F. J., Cheng, C. F., Chen, C. J., Lin, C. Y., Wu, Y. F., Li, T. M., et al. (2019b). Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 57, 30–38. doi:10.1016/j.phymed.2018.09.237

Tsai, F. J., Liu, X., Chen, C. J., Li, T. M., Chiu, J. S., Chuang, P. H., et al. (2019c). Chinese herbal medicine therapy and the risk of overall mortality for patients with liver cancer who underwent surgical resection in Taiwan. Complement Ther. Med. 47, 102213. doi:10.1016/j.ctim.2019.102213

Tsai, F. J., Yang, P. Y., Chen, C. J., Li, J. P., Li, T. M., Chiu, J. S., et al. (2020). Decreased overall mortality rate with Chinese herbal medicine usage in patients with decompensated liver cirrhosis in Taiwan. BMC Complement Med. Ther. 20, 221. doi:10.1186/s12906-020-03010-6

Wang, C., Zhou, X., Wang, Y., Wei, D., Deng, C., Xu, X., et al. (2017). The antitumor constituents from Hedysotis diffusa Wild. Molecules 22, 2101. doi:10.3390/molecules22122101

Wu, C. C., Fang, C. Y., Cheng, Y. J., Hsu, H. Y., Chou, S. P., Huang, S. Y., et al. (2017). Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. J. Biomed. Sci. 24, 2. doi:10.1186/s12929-016-0313-9

Wu, C. C., Chen, M. S., Cheng, Y. J., Ko, Y. C., Lin, S. F., Chiu, I. M., et al. (2019). Emodin inhibits EBV reactivation and represses NPC tumorigenesis. Cancers 11, 1795. doi:10.3390/cancers11111795

Yang, D. H., Kang, J. H., Park, Y. B., Park, Y. J., Oh, H. S., and Kim, S. B. (2013). Association rule mining and network analysis in oriental medicine. PLoS One 8, e59241. doi:10.1371/journal.pone.0059241

Ye, L., Jia, Y., Ji, K. E., Sanders, A. J., Xue, K., Ji, J., et al. (2015). Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol. Lett. 10, 1240–1250. doi:10.3892/ol.2015.3459

Yen, H. R., Liang, K. L., Huang, T. P., Fan, J. Y., Chang, T. T., and Sun, M. F. (2015). Characteristics of traditional Chinese medicine use for children with allergic rhinitis: a nationwide population-based study. Int. J. Pediatr. Otorhinolaryngol. 79, 591–597. doi:10.1016/j.ijporl.2015.02.002

Zhang, Y., Liang, Y., and He, C. (2017). Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine. Chin. Med. 12, 20. doi:10.1186/s13020-017-0140-2

Zhang, Q., Cao, W. S., Wang, X. Q., Zhang, M., Lu, X. M., Chen, J. Q., et al. (2019). Genistein inhibits nasopharyngeal cancer stem cells through sonic hedgehog signaling. Phytother Res. 33, 2783–2791. doi:10.1002/ptr.6464

Zhao, W., Tang, L., Gao, S., Xin, L., Zhang, H., and Li, Y. (2019). Fundiquing extractive promotes the apoptosis of nasopharyngeal carcinoma cells through down-regulating Mcl-1 and Bcl-xL and up-regulating Caspase-3, Caspase-8 and Caspase-9. Artif. Cells Nanomed. Biotechnol. 47, 3904–3912. doi:10.1080/21691401.2019.1667815

Zhu, Y., Song, X., Li, R., Quan, H., and Yan, L. (2019). Assessment of nasopharyngeal cancer in young patients aged < or =30 years. Front. Oncol. 9, 1179. doi:10.3389/fonc.2019.01179

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wang, Wang, Liang, Hung, Chiou, Chen, Tsai, Huang, Chang, Lin, Liao, Huang, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.